16
Total investments
9
Early stage
2
Mid stage
0
Late stage
17y
Years active
Portfolio
12 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
2021
RxLive integrates clinical pharmacists into the healthcare team to create significant financial and clinical value. Implementing and maximizing this value is a discipline we call Value‑Based Pharmacy™. We are a concierge telehealth pharmacy service that connects patients with expert pharmacists in a secure, private and personal way.
RxLive is elevating clinical pharmacy in value-based care. With, My.RxLive, Value-based Pharmacy System (VPS), vertically integrated workflows proactively identify, engage and intervene to optimize impact throughout a population.
RxLive.AI technology and service solutions streamline processes to improve pharmacist efficiency, quality measures and health outcomes. Dynamic analytics visualize the impact of clinical programs throughout the continuum of care and prove the value created by pharmacy.
https://youtu.be/OdTjt7CHzCM
Investor
2021
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-generating medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org.
Were hiring! Learn more at osmind.org/careers
Investor
2021
Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.
Investor
Jul 2020
Halo is focused on creating first-in-class, disease-modifying therapies using innovative approaches to edit the extracellular matrix (ECM). We are exploiting novel insights in ECM biology by selectively editing its components to restore homeostasis in diseases affected by inflammation and fibrosis. Our lead program is aimed to deliver a first in class disease-modifying therapy for pulmonary hypertension.
Investor
Jul 2020
At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun.
We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors.
If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.
Investor
2019
Pragma Bio exists to find cures for undruggable immunological disorders. We use real-world data and synthetic biology to map out multi-layered biological signatures associated with clinical outcomes in order to produce natural chemistry with therapeutic potential.
Investor
2018
Boost Biomes is using the powerful social networks among microbes to provide novel, sustainable solutions to feed and heal people everywhere. Our technology differentiator is the development of a causal understanding of microbial interactions powerful enough to allow the rational construction of designer functional consortia.
Our first products seek to reduce the enormous waste in agricultural products due to crop loss to fungal pests in the field and post-harvest. There is significant need for new biological, organic, safe biopesticides for crops; current chemical products have many challenges, including regulatory burden for growers and safety concerns of consumers.
Investor
2018
MedAnswers builds highly engaged disease communities through easy-to-use engagement platforms for both patients and professionals. We match consumers with a network of trusted experts who can answer their personal questions, provide access to life-affirming clinical trials and use machine learning to match users to research, products and solutions specific to their health needs. Life-sciences companies can receive high-value market data products including hard-to-get behavioral data, natural history data and real world evidence. Researchers can recruit more patients for their clinical trials in half the amount of time with 83% opt-in rates to participate.
Our flagship platform, FertilityAnswers, amassed a 250M+ data set with 65,000 users including behavioral insights, lifestyle, buying and non-buying decision making. These insights span the entire patient journey from struggle to treatment, identifying gaps in access, racial disparities, knowledge disparities, and so much more. With thousands of insights available, the company launched medinsights.medanswers.com for scalable dashboard access for our partners.
The company is rapidly expanding into neurology, oncology and immunology through both out-licensing and in-house brand development.
Investor
2018
Halo derives insights from complex data to enable enterprise customers to accelerate medical advancements.
Investor
2018
Mediphage is a biotech company developing non-viral safe and redosable gene therapies. ministring DNA (msDNA), which is Mediphage’s flagship technology, is a versatile linear covalently closed (LCC) DNA construct that can accommodate large transgenes (> 4.7 kb) and address various applications. The company is evaluating the therapeutic potential of its non-viral platform technology in a number of indications internally and through external collaborations.
Investor
2018
HALO Precision Diagnostics™ changes patient lives and outcomes through early detection of the leading causes of death with precision diagnostics. We accomplish this with a personalized diagnostic ensemble including advanced imaging, genomics, non-invasive liquid biomarkers, and community-based data at scale combined with deep learning algorithms. By optimizing all these solutions under the HALO Diagnostics platform, we provide rapid, precise, actionable results to enable life-changing treatments by physicians for their patients.
Experience · 24 entries
All (24)
Investments (16)
Founder (6)
2021
Investor
2021
RxLive integrates clinical pharmacists into the healthcare team to create significant financial and clinical value. Implementing and maximizing this value is a discipline we call Value‑Based Pharmacy™. We are a concierge telehealth pharmacy service that connects patients with expert pharmacists in a secure, private and personal way.
RxLive is elevating clinical pharmacy in value-based care. With, My.RxLive, Value-based Pharmacy System (VPS), vertically integrated workflows proactively identify, engage and intervene to optimize impact throughout a population.
RxLive.AI technology and service solutions streamline processes to improve pharmacist efficiency, quality measures and health outcomes. Dynamic analytics visualize the impact of clinical programs throughout the continuum of care and prove the value created by pharmacy.
https://youtu.be/OdTjt7CHzCM
Investor
2021
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-generating medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org.
Were hiring! Learn more at osmind.org/careers
Investor
2021
Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.
2020
Investor
Jul 2020
Halo is focused on creating first-in-class, disease-modifying therapies using innovative approaches to edit the extracellular matrix (ECM). We are exploiting novel insights in ECM biology by selectively editing its components to restore homeostasis in diseases affected by inflammation and fibrosis. Our lead program is aimed to deliver a first in class disease-modifying therapy for pulmonary hypertension.
Investor
Jul 2020
At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun.
We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors.
If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.
Show all 24 entries ↓
Investment activity
2009–2021 · 16 investments
Recent (last 2 years)Earlier
